《兴奋收缩耦联和心力衰竭的治疗课件》由会员分享，可在线阅读，更多相关《兴奋收缩耦联和心力衰竭的治疗课件（54页珍藏版）》请在金锄头文库上搜索。
1、田野田野 教授教授哈医大二院心内科兴奋收缩耦联和心力衰竭的治疗兴奋收缩耦联和心力衰竭的治疗TOPICSpExcitation-contraction(EC)couplingExcitationCalciumCyclingContractionpAlterationsofE-CcouplinginHFpInotropicagentsforHFExcitation-contractioncoupling兴奋收缩耦联和心力衰竭的治疗Thepoweroflocomotionisthatwhichcontractsandrelaxesthemuscleswherebythemembersandjoint
2、saremoved,extendedorflexed.Thispowerreachesthelimbsbywayofthenervesandthereareasmanyformsofpowerasthereareofmovement.Eachmusclehasitsownpeculiarpurposeanditobeysthedecreeofthecompositesense.Avicenna(11671248)WilliamHarvey(15781657)HewasanEnglishmedicaldoctor/physician,whoiscreditedwithbeingthefirstt
3、ocorrectlydescribe,inexactdetail,thesystemiccirculationandpropertiesofbloodbeingpumpedaroundthebodybytheheart.Weshalldesignatetheentireseque-nceofreactions:excitation,inwardactinglink,andactivationofcontra-ctionbythetermexcitation-contractioncoupling.ALEXANDER SANDOW,1952(New York University)Sandow
4、A.YaleJBiolMed . 1952.25 (3): 176201 Cardiacexcitationcontractioncouplingistheprocessfromelectricalexcitationofthemyocytetocontractionoftheheart(whichpropelsbloodout).TheubiquitoussecondmessengerCa2+isessentialincardiacelectricalactivityandisthedirectactivatorofthemyofilaments,whichcausecontraction.
5、BersDM.Nature,2002,415(6868):198-205.Excitation兴奋收缩耦联和心力衰竭的治疗ThecardiacactionpotentialAnotabledifferencebetweenskeletalandcardiacmyocytesishoweachelevatesthemyoplasmicCa2+toinducecontraction.Incardiacmyocytes,thereleaseofCa2+fromthesarcoplasmicreticulumisinducedbyCa2+influxintothecellthroughvoltage-
6、gatedcalciumchannels.CalciumCycling兴奋收缩耦联和心力衰竭的治疗PictorialOFCalciumCyclingCa+Ca+Ca+Ca+PlbCa+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Na+Na+Na+Ca+SERCASRRyRL-Type Ca+ChannelNa+/Ca+ ExchangerCa+Sarco
7、lemmaCa+CardiactissueandcellsConductelectricalwavesContractinresponsetoanelectricalstimulus(Guinea-pig ventricular cell)Cardiac tissueFunctionBSarcoplasmicReticulum(SR)PLNandSERCAthesitesofinteractionbetweenPLNandSERCASodium-calciumexchanger(NCX)Two-waytransporter“forward”mode“reverse”modeNa:Ca=3:1C
8、a release Coincides with activation of the contractile machinery Contraction兴奋收缩耦联和心力衰竭的治疗SlidingFilamentTheoryA.F.Huxley1954EMevidenceforslidingfilamenttheoryThemicrographshowsmyosinboundtoactinThemolecularbasisformyocardialcontractionThin filament (Actin ,Tropom-yosin, Troponin) Thick filament (My
9、osin)Other proteinsChien,K.R.,1999ZZTitin28,000 amino acids (3MDa) the largest protein known in mammals.Titin MYOSIN MW 480 kDaForms thick filamentsHydrolyses ATPInteracts with F-actin 300-400 myosin molecules per 1 filamentS1S1150 nmThickFilamentProteinsRLCELCATP Binding SiteActin Binding SiteATP （
10、Myosin） ADP + Pi + EnergyMyosinHead(S1)molecularmotorofmusclecontractionG-ActinF-ActinG to F actin MW 42 kDaThe blue and grey molecules are actin monomers (MW 42.000)Ken C. Holmes: Max-Planck-Institute Takeda, S. et al. Nature 424, 35 41, 2003 HCTnCHCTnIHCTnTTropomyosinTropomyosinbinding regionHyper
11、variable regionCrystalStructureofHumanCardiacTroponinGordonetal.2001RegulationofthinfilamentincontractionMuscleContractionAlterationsinE-CcouplinginHF兴奋收缩耦联和心力衰竭的治疗RyR2channelleakHeart FailurePDE4D levelsloss of FKBP12.6RyR2 channel leakArrhythmia and progression of heart failure.JefferyDMolkentin.N
12、atureMedicine11,1284-1285(2005)PLNSERCA2ainteractionsinphysiologicalanddiseasedcardiacfunctionStevenR.Houser.JMolCellCardiol32,15951607(2000)InotropicAgentsforHF兴奋收缩耦联和心力衰竭的治疗InotropicAgentsand-blockerDigitalisPhosphodiesteraseinhibitor-adrenoceptorblockerDigitalis(200years)DigilispurpureaPurplefoxg
13、loveWilliamWithering(17411799)MechanismofActionDigitalisOtherstudySome evidence suggests that the benefits of digitalis may be related in part to enzyme inhibition in noncardiac tissues. Inhibition of Na-KATPaseinvagalafferentfibers acts to sensitize cardiac baroreceptors, which in turn reducessympa
14、theticoutflow from the central nervous system.In addition, by inhibitingNa-KATPaseinthekidney, digitalis reduces the renal tubular reabsorption of sodium; the resulting increase in the delivery of sodium to the distal tubules leads to the suppressionofreninsecretion from the kidneys.ThamesMD.CircRes
15、.1979;44:815.FergusonDWetal.Circulation.1989;80:6577.TorrettiJetal.AmJPhysiol.1972;222:1398405.50403020100Placebon=3403Digoxinn=3397480122436Mortality %NEnglJMed1997;336:525Monthsp=0.8N=6800NYHA II-IIIDIGtrail(1997)ACC/AHAHFguideline2009Long-termuseofaninfusionofapositiveinotropicdrugmaybeharmfuland
16、isnotrecommendedforpatientswithcurrentorpriorsymptomsofHFandreducedLVEF,exceptaspalliationforpatientswithend-stagediseasewhocannotbestabilizedwithstandardmedicaltreatment(StageD).(ClassIII,Level of Evidence: C)Continuousintravenousinfusionofapositiveinotropicagentmaybeconsideredforpalliationofsympto
17、msinpatientswithrefractoryend-stageHF(StageD).(Class IIb, Level of Evidence: C)PhosphodiesteraseinhibitorThedifferentformsorsubtypesofphosphodiesterasewereinitiallyisolatedfromratbrainsbyUzunovandWeissin1972andweresoonafterwardsshowntobeselectivelyinhibitedinthebrainandinothertissuesbyavarietyofdrug
18、sThepotentialforselectivephosphodisteraseinhibitorsastherapeuticagentswaspredictedasearlyas1977byWeissandHait.Thispredictionmeanwhilehasprovedtobetrueinavarietyoffields.Uzunov,P.andWeiss,BBiochim.Biophys.Acta284:220-226,1972Weiss,B.andHait,W.N.:Ann.Rev.Pharmacol.Toxicol.17:441-477,1977.Phosphodieste
19、rase-3inhibitorPDEI cAMPAMPPDE3YuanJamesRao,(2009)MechanismofactionAs a result of its high expression in both the vasculature and the airways, PDE3 was identified as a potential therapeutic target in cardiovascular disease and asthma.-Augment myocardial contractility -Relax vascular and airway smoot
20、h muscle-Inhibit platelet aggregation -Induce lipolysisBARNESP.J.etal.Pharmacol.Rev.1988;40:4984.MANGANIELLOV.C.,etal.CellSignal.1995;7:445455.“IwishIhadmybeta-blockershandyHislandmarkinventionofpropranololin1964andtheH2-receptorantagonist,cimetidine,in1972earnedhimtheNobelPrizeinMedicinein1988.Jame
21、s W. Black -adrenoceptorReceptorBlockersMechanismofactionDensityof1receptorsInhibitcardiotoxicityofcatecholaminesNeurohormonalactivationHRAntiischemicAntihypertensiveAntiarrhythmicAntioxidant,Antiproliferative1001009090808060607070505024240 02020161612128 84 42828PlaceboPlaceboCarvedilolCarvedilolMo
22、nthsMonthsN=2289III-IVNYHANEJM 2001;344:1651NEJM 2001;344:1651Survival%Survival%p p=0.00014=0.0001435% RR 35% RR COPERNICUSStudy(2001)ACC/AHAHFguideline2009Useof1ofthe3betablockersproventoreducemortality(i.e.,bisoprolol,carvedilol,andsustainedreleasemetoprololsuccinate)isrecommendedforallstablepatie
23、ntswithcurrentorpriorsymptomsofHFandreducedLVEF,unlesscontraindicated. (Class I, Level of Evidence: A)Whentostart?PatientstableNophysicalevidenceoffluidretentionNoneedforI.V.inotropicdrugsStartACE-I/diureticfirstStartLow,IncreaseSlowlyIncreasethedoseevery2-4weeksRisksoftreatmentFluidRetentionAndWors
24、eningHF(intensification of conventional therapy)FatigureBradycardiaAndHeartBlockHypotension(block alpha-1receptors)Reviewtreatment(+/-diuretics,otherdrugs)ReducedoseConsidercardiacpacingDiscontinuebetablockeronlyinseverecasesHowshouldclinicaldeteriorationbemanagedinpatientswhohavebeentakingabetabloc
25、kerforlongperiodsoftime(morethan3months)?ifpatientsdevelopfluidretention,withorwithoutmildsymptoms,itisreasonabletocontinuethebetablockerwhilethedoseofdiureticisincreased.Ifthedeteriorationinclinicalstatusischaracterizedbyhypoperfusionorrequirestheuseofintravenouspositiveinotropicdrugs,itmaybepruden
26、ttohaltorsignificantlyreducetreatmentwithbetablockerstemporarilyuntilthestatusofthepatientstabilizes.Insuchpatients,positiveinotropicagentswhoseeffectsaremediatedindependentlyofthebetareceptor(e.g.,aphosphodiesteraseinhibitorsuchasmilrinone)maybepreferred.AdamsKF,Lindenfeld J,etal.HFSA2006HeartFailu
27、reGuideline.JCardFail2006;12:e1Usewithcautioninpatientswith:-Diabeteswithrecurrenthypoglycemia-Asthmaorrestinglimbischemia.lUsewithconsiderablecautioninpatientswithmarkedbradycardia(55bpm)ormarkedhypotension(SBP80mmHg).lNotrecommendedinpatientswithasthmawithactivebronchospasm.CONCLUSIONpVIEW1:LongtermpVIEW2:ComprehensivepVIEW3:FromBasictoClinicTHANKS FOR YOUR ATTENTION!
